EU Clears GSK-Novartis And Mylan-Abbott Deals, With Minor Conditions
This article was originally published in The Pink Sheet Daily
Meningitis and tetanus-diphtheria vaccines and smoking cessation products will be divested by GSK in Europe, and B-Raf and MEK inhibitors by Novartis, while Mylan will divest four generics in five markets.
You may also be interested in...
The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.